American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–65.
Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204–11.
Asherson P, Trzaskowski M. Attention-deficit/hyperactivity disorder is the extreme and impairing tail of a continuum. J Am Acad Child Adolesc Psychiatry. 2015;54:249–50.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for ADHD. Nat Genet. 2019;51:63–75.
Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24:562–75.
Akutagava-Martins GC, Rohde LA, Hutz MH. Genetics of attention-deficit/hyperactivity disorder: an update. Expert Rev Neurother. 2016;16:145–56.
Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry. 2010;15:1053–66.
Hwang IW, Lim MH, Kwon HJ, Jin HJ. Association of LPHN3 rs6551665 A/G polymorphism with attention deficit and hyperactivity disorder in Korean children. Gene. 2015;566:68–73.
Ribasés M, Ramos-Quiroga JA, Sánchez-Mora C, Bosch R, Richarte V, Palomar G, et al. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study. Genes, Brain Behav. 2011;10:149–57.
Bruxel EM, Salatino-Oliveira A, Akutagava-Martins GC, Tovo-Rodrigues L, Genro JP, Zeni CP, et al. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. Genes, Brain Behav. 2015;14:419–27.
Kappel DB, Schuch JB, Rovaris DL, da Silva BS, Cupertino RB, Winkler C, et al. Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;79:120–7.
Huang X, Zhang Q, Gu X, Hou Y, Wang M, Chen X, et al. LPHN3 gene variations and susceptibility to ADHD in Chinese Han population: a two-stage case-control association study and gene-environment interactions. Eur Child Adolesc Psychiatry. 2019;28:861–73.
Lange M, Norton W, Coolen M, Chaminade M, Merker S, Proft F, et al. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. Mol Psychiatry. 2012;17:946–54.
Wallis D, Hill DS, Mendez IA, Abbott LC, Finnell RH, Wellman PJ, et al. Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res. 2012;1463:85–92.
O’Sullivan ML, Martini F, von Daake S, Comoletti D, Ghosh A. LPHN3, a presynaptic adhesion-GPCR implicated in ADHD, regulates the strength of neocortical layer 2/3 synaptic input to layer 5. Neural Dev. 2014;9:1–11.
Orsini CA, Setlow B, DeJesus M, Galaviz S, Loesch K, Ioerger T, et al. Behavioral and transcriptomic profiling of mice null for Lphn3, a gene implicated in ADHD and addiction. Mol Genet Genom Med. 2016;4:322–43.
Martinez AF, Abe Y, Hong S, Molyneux K, Yarnell D, Löhr H, et al. An ultraconserved brain-specific enhancer within ADGRL3 (LPHN3) underpins attention-deficit/hyperactivity disorder susceptibility. Biol Psychiatry. 2016;80:943–54.
Rovira P, Demontis D, Sanchez-Mora C, Zayats T, Klein M, Roth Mota N, et al. Shared genetic background between children and adults with attention deficit/hyperactivity disorder. 2019. https://doi.org/10.1101/589614.
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190–1.
Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.handbook.cochrane.org.
Acosta MT, Swanson J, Stehli A, Molina BSG, Martinez AF, Arcos-Burgos M, et al. ADGRL3 (LPHN3) variants are associated with a refined phenotype of ADHD in the MTA study. Mol Genet Genom Med. 2016;4:540–7.
Dark C, Homman-Ludiye J, Bryson-Richardson RJ. The role of ADHD associated genes in neurodevelopment. Dev Biol. 2018;438:69–83.
The Brainstorm Consortium, Anttila V, Bulik-Sullivan B, Finucane HK, Walters R, Bras J, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360:eaap8757. https://doi.org/10.1126/science.aap8757.
Cross-Disorder Group of the Psychiatric Genomics C. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984–94.
Visscher PM, Wray NR, Zhang Q, Sklar P, Mccarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101:5–22.
Choudhry Z, Sengupta SM, Grizenko N, Fortier ME, Thakur GA, Bellingham J, et al. LPHN3 and attention-deficit/hyperactivity disorder: Interaction with maternal stress during pregnancy. J Child Psychol Psychiatry Allied Discip. 2012;53:892–902.
Jain M, Vélez JI, Acosta MT, Palacio LG, Balog J, Roessler E, et al. A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD. Mol Psychiatry. 2012;17:741–7.
Acosta MT, Vélez JI, Bustamante ML, Balog JZ, Arcos-Burgos M, Muenke M. A two-locus genetic interaction between LPHN3 and 11q predicts ADHD severity and long-term outcome. Transl Psychiatry. 2011;1:1–8.
Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: from polygenic to omnigenic. Cell. 2017;169:1177–86.
Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015;172:967–77.
Riglin L, Collishaw S, Thapar AK, Dalsgaard S, Langley K, Smith GD, et al. Association of genetic risk variants with attention-deficit/hyperactivity disorder trajectories in the general population. JAMA Psychiatry. 2016;73:1285.